Objective: To evaluate the risk of cancers with and without a known infectious cause in HIV-infected persons.
Introduction
With effective combination antiretroviral therapy (ART) use, HIV-infected persons in developed countries have experienced a precipitous decline in AIDS-defining cancers (ADCs) and opportunistic infections, but a rise in other chronic conditions associated with aging. In the ARTera, non-AIDS-defining cancers (NADCs) are now more common than ADCs [1] [2] [3] . Despite this change in the distribution of cancers, ADCs and many NADCs continue to pose a higher risk for HIV-infected persons than for the general population [2, 4] . NADCs that are consistently found more commonly among HIV-infected persons include Hodgkin's lymphoma, skin, lung, anal squamous cell, and oral cavity/pharynx cancers, whereas others including prostate and breast cancer appear to occur less frequently [5] .
One reason for the continued higher risk of certain cancers among HIV-infected persons is the higher prevalence of traditional cancer risk factors such as smoking [6] [7] [8] , alcohol use [7, 9] , and oncogenic virus coinfection, including human papillomavirus (HPV) or hepatitis B and C [10] [11] [12] [13] . At the same time, HIV infection and associated immunodeficiency may also contribute to the higher risk. It is possible, for example, that the impaired immune system may result in the general reduced immune surveillance for malignant cells [14] . Alternatively, an impaired ability of the immune system to suppress oncogenic viruses may also result in a higher risk of these cancers [12, 15] .
However, prior studies have been limited by small sample sizes, inclusion of AIDS cases only, and a lack of HIVuninfected controls. Here, we compared the incidence of cancers between a large cohort of HIV-infected and matched HIV-uninfected persons from the same integrated healthcare system, Kaiser Permanente. This setting provides a unique perspective on this topic as all participants have comprehensive medical insurance coverage, and thus outcome differences attributable to variations in access to care and preventive services are reduced. In addition, the comprehensive HIV and cancer disease registries maintained at Kaiser Permanente allow for high quality outcome ascertainment.
An additional unique feature of this study is the exploration of the epidemiology of cancers with and without a known infectious cause (referred to throughout as infectionrelated and infection-unrelated NADC). Specifically, we hypothesized that infection-related NADC would pose the highest risk for HIV-infected compared with HIVuninfected persons. We further postulated that the higher risk of infection-related NADC for HIV-infected persons may decrease during the ARTera with improving immune function in HIV-infected persons.
Methods
Study design, setting, and participants We conducted a retrospective cohort study from 1996 to 2007 of adult HIV-infected and HIV-uninfected persons within Kaiser Permanente Northern California (KPNC) and Kaiser Permanente Southern California (KPSC), which are both large integrated healthcare delivery systems providing comprehensive medical services to more than 6 million health plan members, who are demographically representative of all insured Californians [16] .
The HIV-infected study population here consisted of persons at least 18 years of age with Kaiser Permanente membership starting in or after 1996 in KPNC or 2000 in KPSC, corresponding to the earliest year in the ART era with comprehensive coverage for the respective HIV registries. The start of follow-up (i.e., index date) for HIV-infected patients was assigned as the earliest date on or after 1 January 1996 (1 January 2000 for KPSC) when a member was both at least 18 years of age and known to be HIV-infected. Next, HIV-uninfected persons were selected from the pool of active health plan members at least 18 years of age during index years observed for HIVinfected persons. HIV-uninfected persons were eligible for selection during all years when they were members, but once selected as a control, were excluded from other index year selection pools. HIV-uninfected persons were also excluded if they were ever included in the HIV registries through 2007. HIV-uninfected persons were then frequency-matched 10 : 1 by index year, age on 31 December of the index year (5-year age groups), sex, and medical center. The start of follow-up for HIVuninfected patients was assigned as the earliest date after 1 January of the index year they were selected when they were at least 18 years of age.
Data sources
The KPNC HIV registry includes all known cases of HIV infection since the early 1980s and the KPSC HIV registry includes cases identified since 2000. Confirmation of cases is done by medical chart review and comparisons of case lists with HIV clinics. Data elements maintained in the HIV registries include sex, race/ethnicity, HIV exposure risk (i.e., men who have sex with men, injection drug use, heterosexual, other), dates of known HIV and AIDS diagnoses, and dates of death. We identified all incident cancers by linkage with the KPNC and KPSC cancer registries. The Kaiser Permanente cancer registries are contributing sites to the Surveillance, Epidemiology, and End Results (SEER) program registry and Kaiser Permanente registry's data are of comparable accuracy and completeness to that of SEER. All medical facilities in California are required by law to report all newly diagnosed cases of cancer to the California Cancer Registry (CCR), through a network of 10 regional registries that together capture the cancer incidence experience of the entire state. All registries follow SEER practices in verifying and coding incident cancers. SEER requirements include categorization of histopathology, invasiveness, tumor size, extension, and lymph node involvement.
Cancer endpoints
The primary endpoints examined were incident ADC and NADC diagnosed on or after each person's index date. Persons with a history of the cancer of interest in the 2 years prior to their index date were excluded. A subset of NADCs with a known infectious cause were further categorized as infection-related NADCs [17] [18] [19] : these were vagina, vulva, penis, squamous cell anal, and certain squamous cell oral cavity/pharynx cancers defined by Chaturvedi et al. [19] , which are all HPV related; liver cancer which is hepatitis B and C related; stomach cancer which is Helicobacter pylori related; and Hodgkin's lymphoma which is Epstein-Barr virus related. All other cancers were considered infection-unrelated NADC. Persons with multiple cancers contributed events to each applicable category.
Statistical methods
Participants were followed from first enrollment in the cohort until the earliest of a cancer diagnosis, health plan disenrollment, death or 31 December 2007. We first computed cancer incidence rates per 100 000 personyears. Next, rate ratios for the incidence of cancer in HIV-infected compared with HIV-uninfected persons were obtained from Poisson regression models adjusted for attained age, sex, race/ethnicity, and calendar year. Race/ethnicity for those with missing information was imputed based on participant's age at index and census block group characteristics, including, median household income, % less than high school diploma, % white, % black, % Hispanic, and % Asian. Next, standard multiple imputation methods [20] were used to obtain adjusted rate ratios. However, inferences were unchanged for all cancers compared with models that did not include race/ ethnicity (data not shown); thus, subsequent analyses did not consider this factor.
Next, we examined linear changes over time in the incidence of cancers in both HIV-infected and HIVuninfected persons. These models included age, sex, a linear term for calendar period (1996-1999, 2000-2003, 2004-2007) and an HIV/calendar period interaction term. Finally, we evaluated whether the rate ratio for HIV infection status changed over time during 1996-1999, 2000-2003, and 2004-2007 . These models included age, sex, categorical variables for each calendar period, and corresponding HIV/calendar period interaction terms. Changes of the rate ratio for HIV infection status over time were assessed by the likelihood ratio test.
Analyses were performed with SAS (Version 9.1; Cary, North Carolina, USA), using proc GENMOD for Poisson regression and proc MI and MIANALYZE for multiple imputation. The institutional review boards at Kaiser Permanente approved this study and provided waivers of informed consent.
Results
We identified Table 1 ). The HIV-infected cohort had a mean age at start of follow-up of 41 years, was predominantly male (90%), white (56%), and among those with known HIV exposure risk, was predominantly men who have sex with men (74%). HIVuninfected persons in this study were identical to HIVinfected persons for matching factors of age, sex and index year. The HIV-uninfected cohort had a lower percentage of whites and blacks, but a higher percentage of Asians and Hispanics compared with the HIV-infected cohort, among those with known race/ethnicity. Figure 1 displays the similarly increasing mean age of HIV-infected and HIV-uninfected persons during study follow-up. CD4
þ T-cell counts also increased over time for HIVinfected persons with a mean of 312 in 1996 and 524 in 2007.
Among HIV-infected persons, 552 had an ADC, 221 had an infection-related NADC, and 388 had an infectionunrelated NADC (Table 2) . Thus, counting all ADCs, which have viral etiologies [17, 18] , and infection-related NADCs, 67% of cancers in HIV-infected persons had a known infectious cause. In contrast, among HIVuninfected persons, 179 had an ADC, 284 had an infection-related NADC, and 3418 had an infectionunrelated NADC, corresponding to only 12% of cancers with a known infectious cause.
Adjusted rate ratios comparing HIV-infected with HIVuninfected persons (reference) were 37.7 (P < 0.001) for ADC, 9.2 (P < 0.001) for infection-related NADC, and 1.3 (P < 0.001) for infection-unrelated NADC (Table 2) .
Rates for most individual infection-related NADCs were significantly elevated in HIV-infected persons, including anal squamous cell (rate ratio ¼ 101.6, P < 0.001), vagina/vulva (rate ratio ¼ 19.5, P < 0.001), Hodgkin's lymphoma (rate ratio ¼ 19.4, P < 0.001), penis (rate ratio ¼ 5.8, P ¼ 0.006), liver (rate ratio ¼ 2.7, P < 0.001), and HPV-related oral squamous cell cancers (rate ratio ¼ 2.0, P ¼ 0.034). Stomach cancer was the only individual infection-related NADC not associated with HIV infection. Infection-unrelated NADCs with increased rates in HIV-infected persons were other anal (rate ratio ¼ 35.3, P < 0.001), nonmelanoma skin (rate ratio ¼ 10.6, P < 0.001), other head and neck (rate ratio ¼ 2.7, P < 0.001), lung (rate ratio ¼ 1.9, P < 0.001), and melanoma (rate ratio ¼ 1.5, P ¼ 0.006); HIV-infected persons also had a lower rate of prostate cancer with a rate ratio of 0.7 (P ¼ 0.002). Other infection-unrelated NADCs were not associated with HIV infection.
As shown in Fig. 2 , there was an 8% annual decline (P < 0.001) in infection-related NADCs for HIVinfected persons compared with a 6% annual increase (P ¼ 0.007) for HIV-uninfected persons (P < 0.001 for difference by HIV status). These trends were similar to trends for ADC rates, which declined 12% annually (P < 0.001) for HIV-infected persons and increased 5% annually (P ¼ 0.091) for HIV-uninfected persons (P < 0.001 for difference by HIV status; data not shown).
Results for two individual infection-related NADCs, anal squamous cell cancer and Hodgkin's lymphoma, are also shown in Fig. 2 . For anal squamous cell cancer, there was a 9% annual decline (P ¼ 0.002) for HIV-infected persons and a 4% annual decline (P ¼ 0.68) for HIV-uninfected persons (P ¼ 0.57 for difference by HIV status). The risk of Hodgkin's lymphoma did not change significantly over time for HIV-infected persons (P ¼ 0.50), but increased by 17% (P ¼ 0.035) among HIV-uninfected persons (P ¼ 0.032 for difference by HIV status). Other infectionrelated NADCs did not change significantly over time for HIV-infected persons and demonstrated similar trends to HIV-uninfected persons (data not shown). Of note, there were borderline differences comparing annual changes in HIV-infected and HIV-uninfected vagina/vulva cancer rates (À6 vs. 17%; P ¼ 0.087).
The crude rate for infection-unrelated NADCs steeply increased over time for HIV-infected and HIV-uninfected persons (Fig. 2) , which was explained by the advancing age of the cohort (Fig. 1) . In adjusted models, infection-unrelated NADC rates did not change substantially over time with a 3% annual increase (P ¼ 0.15) for HIV-infected persons and a 1% annual increase (P ¼ 0.066) for HIV-uninfected persons (P ¼ 0.44 for difference by HIV status; Fig. 2 ). Trends in rates for all individual infection-unrelated NADCs were similar by HIV infection status, and none showed significant changes among HIV-infected persons (data not shown). Of note were borderline differences comparing annual changes in HIV-infected and HIV-uninfected colorectal cancer rates (9 vs. À1%; P ¼ 0.12; data not shown).
We also evaluated whether the association of HIV infection status and cancer risk changed over time ( 
Discussion
We determined that infection-related cancers (ADC and infection-related NADC combined) comprised almost 70% of all cancers in HIV-infected persons enrolled in an integrated healthcare system in California compared with only 12% in HIV-uninfected persons of similar age and sex. HIV-infected persons had a more than nine-fold increased risk of infection-related NADC compared with HIV-uninfected persons, which was largely influenced by differences in the risk of anal squamous cell cancer and Hodgkin's lymphoma. HIV-infected persons also had a 30% increased risk of infection-unrelated NADC compared with HIV-uninfected persons, including a higher risk of other anal, skin, other head and neck, and lung cancers, but lower risk of prostate cancer. Infectionrelated NADC risk declined over time for HIV-infected persons and increased for HIV-uninfected persons. In contrast, the overall infection-unrelated NADC risk did not change over time for HIV-infected or HIVuninfected persons.
The substantially greater risk of cancer with a known infectious cause in HIV-infected persons compared with HIV-uninfected persons may be explained by higher virus coinfection rates, as demonstrated by others for human herpesvirus-8, HPV and hepatitis B and C [10] [11] [12] [13] . However, general population prevalence for certain viruses, such as Epstein-Barr virus [21] , is very high and cannot account entirely for the large difference observed here for Hodgkin's lymphoma. Alternatively, the greater risk of infection-related cancer observed for HIV-infected persons could be further explained by the fact that the suppressed immune system in HIV-infected persons may reduce the ability to control infections and therefore suppress the oncogenic viral process. This mechanism is supported by a large meta-analysis by Grulich et al. [17] who compared cancers elevated in persons with HIV infection and organ transplant recipients. These two very different populations have few shared risk factors for cancer except both populations have suppressed immune systems [17, 22] . Most of the cancers seen with higher frequency in both populations compared with general population rates had a known infectious cause, including ADC, as well as the same infection-related NADC we report here. Others have demonstrated a higher risk of Hodgkin's lymphoma [2, 6, [23] [24] [25] [26] , oral cavity/pharynx [2, 23] , anal [26, 27] , liver [22] , and penis [23] cancers with advanced immunosuppression measured mainly by closer proximity to an AIDS diagnosis [2, [23] [24] [25] or low CD4 þ T-cell counts [4, 6, 26, 27] . One study, however, indicated a nonlinear association of Hodgkin's lymphoma risk and CD4 þ T-cell counts [28] .
Further evidence of a strong link between immune function and infection-related cancer risk is provided by our observation that the increased risk of both ADC and P value tests overall difference in rate ratio over the three calendar periods.
c Few events for certain cancers among either HIV-positive or HIV-negative persons precluded the evaluation of calendar-era-specific rate ratios, including penis, vagina/vulva, and stomach cancers among infection-related cancers and other anal, nonmelanoma skin, sarcomas, and testes cancers among infection-unrelated cancers. Using definition described by Chaturvedi et al. [19] .
e Multiple myeloma and leukemia.
infection-related NADC in HIV-infected persons compared with HIV-uninfected persons has narrowed in recent years. This observation is consistent with improvements during the ART era in immune function possibly leading to better control of coinfections [12, 15] . In fact, a recent study demonstrated that prolonged ART use predicts hepatitis B virus clearance [29] , although studies of the effect of ART on other viruses were inconclusive, including hepatitis C [30] , anal HPV [31] , cervical HPV [32] , and Epstein-Barr virus [33] . Others have actually demonstrated increases in the incidence of Hodgkin's lymphoma [2, 4] , anal cancer [4, 27, 34] , and liver [2] cancer during the ARTera, suggesting that these cancers may not be strongly associated with immune reconstitution resulting from ART use. It is not clear why trends are somewhat different in our study, as we observed no changes over time in HIV-infected persons for any cancer in adjusted models, with the exception of declines in anal squamous cell cancer. One possible explanation is that many prior studies compared rates between the pre-ART and ART eras, whereas ours focused only on the ART era. Piketty et al. [27] , for example, in the largest study focusing on anal cancer, found an increasing trend for years 1992-2004, but no change for years 1999-2004. It is also possible that trends may be different for certain subgroups. Our cohort of predominantly HIVinfected white men having sex with men (MSM) had very high anal squamous cell cancer rates early in the ARTera. Therefore, it is possible that improvements in immune function may have a bigger impact in our population. Nevertheless, our findings need replication in other settings.
We also report here our finding that the risk of infectionunrelated cancers is only marginally increased in HIVinfected persons compared with HIV-uninfected persons. The meta-analysis by Grulich et al. [17] demonstrated that other cancers not known to be associated with an infection were also elevated in both immunosuppressed populations, that is, HIV-infected persons and transplant recipients, including lung and kidney cancers, multiple myeloma, and leukemia. Others have linked infectionunrelated cancers and immunosuppression [2, 23, 24, 35, 36] , most commonly for lung cancer [2, 23, 35] . However, because the reported increased risk of infection-unrelated cancer is not large, results are more likely to be attributed to unmeasured confounding. Unfortunately, few cohorts have the necessary data for complete adjusted analyses. A recent study of skin cancer suggested that the higher risk of melanoma for HIV-infected persons was more likely due to confounding by sun exposure or perhaps increased medical surveillance than due to immunosuppression [37] . However, there is some indication that the excess risk of lung cancer in HIV-infected persons remains even after accounting for cigarette use [35, 38, 39] . Thus, a general effect of immune function on some infection-unrelated cancers is possible, but further research is warranted. The major strength of our study is the selection and follow-up of large, well characterized populations of HIV-infected persons and matched HIV-uninfected persons from the same healthcare system. Study results are likely to be highly generalizable to those with access to healthcare as Kaiser Permanente provides care to approximately 30% of all insured Californians in its most populated areas, and data indicate members are very similar to the local surrounding and statewide population with respect to age, sex, and race/ethnicity, with only slight underrepresentation of those in lower and higher income and education categories [16] . Furthermore, demographics of HIV-infected Kaiser Permanente members are very similar to reported AIDS cases in California [40] . Another strength is the high quality case ascertainment of HIV infection status and cancer diagnoses. Finally, this analysis is unique in that we evaluated differences in the epidemiology of cancers with and without a currently known infectious cause.
In summary, we found that almost 70% of cancers in HIVinfected persons have a currently known infectious cause compared with only 12% in HIV-uninfected persons. These results have implications for prevention of cancers in HIV-infected persons. First, we found little evidence for the need for a different screening approach compared with general guidelines for breast, prostate, or colorectal cancer among HIV-infected persons. However, the higher risk of lung cancer should be evaluated further including the possible association of this cancer with immune function, and the need for greater smoking risk reduction. Prevention efforts in HIV-infected persons, however, should continue to focus on infection-related cancers, including the evaluation of more routine vaccinations for infections such as hepatitis B, and possibly the extension of the recently approved HPV vaccine to adolescent boys. However, the HPV vaccine has not been evaluated in HIV-infected persons, nor has it been evaluated for the prevention of HPV-associated cancers other than cervical cancer. For anal squamous cell cancer, universal screening guidelines for the detection of early lesions may also greatly benefit this population. Finally, our study supports the concept of earlier initiation of ART [41, 42] , as the burden of infection-related cancers may be reduced further with improved immune function.
